Evelo Biosciences, Inc.

OTCPK:EVLO Stock Report

Market Cap: US$1.9k

Evelo Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure6.4yrs
Board average tenureno data

Recent management updates

Recent updates

Analysis Article • Aug 18

Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Aug 11

Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03

Evelo Biosciences press release (NASDAQ:EVLO): Q2 GAAP EPS of -$0.40 beats by $0.03. As of June 30, 2022, cash and cash equivalents were $92.0M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021.
Seeking Alpha • Jul 18

Marella Thorell is the new finance chief of Evelo Biosciences

Evelo Biosciences (NASDAQ:EVLO) appoints 25 years of finance and operations experienced Marella Thorell as CFO, effective September 1, 2022. Most recently she served as Chief Accounting Officer and previously as Head of Finance of Centessa Pharmaceuticals.
Seeking Alpha • Jun 06

Evelo Biosciences: Hope After Dilution?

Today, we put Evelo Biosciences in the spotlight for the first time. The company has several potential catalysts on the horizon. The company also recently executed a large direct offering and brought aboard some strategic advisors as well. A full investment analysis follows in the paragraphs below.
Analysis Article • Mar 21

Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 25

Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 11

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

If you want to know who really controls Evelo Biosciences, Inc. ( NASDAQ:EVLO ), then you'll have to look at the makeup...
Analysis Article • Dec 15

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Evelo Biosciences, Inc. ( NASDAQ:EVLO...
Analysis Article • Dec 11

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

A look at the shareholders of Evelo Biosciences, Inc. ( NASDAQ:EVLO ) can tell us which group is most powerful. Large...

CEO

Evelo Biosciences has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Craig Jalbert
President2.7yrsno datano data
Chun Zhang
Chief Technical Operations & Quality Officer6.4yrsno datano data
Leslie Wardwell-Scott
VP and Head of Corporate Development & Strategic Integration4.1yrsno datano data
Andrea Itano
Head of Research6.4yrsno datano data
Duncan McHale
Chief Medical Officer8.4yrsUS$1.23mno data
Douglas Maslin
Senior Director & Immunology Clinical Leadno datano datano data
6.4yrs
Average Tenure

Experienced Management: EVLO's management team is seasoned and experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 17:33
End of Day Share Price 2026/07/08 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evelo Biosciences, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Gary NachmanBMO Capital Markets Equity Research
Clarence PowellBMO Capital Markets Equity Research